Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Werewolf Therapeutics Inc

HOWL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.40

▲ +4.84%

Market Cap $19.67M · Vol 47.46K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$19.67M

Micro Cap

Div Yield

N/A

EPS Growth

+27.02%

YoY

RSI (14)

42.51

Momentum

Beta

0.33

vs Market

52W High

$2.36

82.82% below

52W Low

$0.27

49.89% above

Volume

47.46K

Avg 109.99K

P/B

1.24

Price-to-book

ROE

N/A

Return on equity

Free Float

98.60%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Werewolf Therapeutics Inc (HOWL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HOWL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.91%

+17.61%

-25.41%

-38.08%

YTD

-36.12%

-69.34%

-83.88%

-97.20%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-60,822,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-61.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.24
P/FCF	N/A
EPS Growth	+27.02%
Outstanding Shares	48.60M

Technical Indicators

50-Day SMA	$0.38
200-Day SMA	$0.68
RSI (14)	42.51
Beta	0.33
52-Week High	$2.36
52-Week Low	$0.27

Volume Today	47.46K
Avg Daily Volume (30D)	109.99K
Relative Volume	0.43x
Volatility (10D)	69.45
Volatility (30D)	139.66
Free Float	98.60%

Analyst Consensus

BUY

Current Price $0.40

Mean Target $7.00

52W Low$0.27 52W High$2.36

Current

Target

$0.27 $2.36

Current Analyst target

+1,629.68% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00QXQ9XL3

ISINUS95075A1079

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.